Section Arrow
Quote
ESPR.NASDAQ
- Esperion Therapeutics
Quotes are at least 15-min delayed:2024/05/20 09:01 EDT
Last
 --
-- (--)
Day High 
-- 
Prev. Close
2.36 
1-M High
2.6 
Volume 
-- 
Bid
2.4
Ask
2.42
Day Low
-- 
Open
-- 
1-M Low
1.71 
Market Cap 
447.13M 
Currency USD 
P/E -- 
%Yield 0 
10-SMA 2.25 
20-SMA 2.13 
50-SMA 2.28 
52-W High 3.4 
52-W Low 0.7 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.90/1.18
Enterprise Value
711.74M
Balance Sheet
Book Value Per Share
-1.55
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
116.33M
Operating Revenue Per Share
0.54
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
ZTSZOETIS----0.000%-- 
YCBD PRAcbdMD----0.000%-- 
YCBDcbdMD----0.000%-- 
VTRSViatris----0.000%-- 
UPCUniverse Pharmaceuticals----0.000%-- 
Quotes are at least 15-min delayed：2024/05/20 09:01 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.